We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00564161
First Posted: November 27, 2007
Last Update Posted: September 2, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hadassah Medical Organization
November 25, 2007
November 27, 2007
September 2, 2016
January 2008
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00564161 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants
VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
CSF.
Non-Probability Sample
preterm infants.
  • Preterm Infants With White Matter Damage
  • Preterm Infants Developing Normally
Not Provided
  • 1
  • 2
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
January 2009
Not Provided

Inclusion Criteria:

  • Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

  • Preterm with IVH or known infection or meningitis.
Sexes Eligible for Study: All
25 Weeks to 40 Weeks   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00564161
606060-HMO-CTIL
606060-HMO-CTIL
No
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: Talya Dor, MD Hadassah Medical Organization
Hadassah Medical Organization
November 2007